SPS
SUPN icon

Susquehanna Portfolio Strategies’s Supernus Pharmaceuticals SUPN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4M Sell
116,160
-26,022
-18% -$1.25M 0.09% 266
2026
Q1 		$7.35M Hold
142,182
– – 0.11% 234
2025
Q4 		$7.07M Sell
142,182
-13,388
-9% -$651K 0.11% 247
2025
Q3 		$7.43M Buy
155,570
+108,253
+229% +$4.36M 0.12% 239
2025
Q2 		$1.49M Buy
+47,317
New +$1.52M 0.03% 431

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Susquehanna Portfolio Strategies's SUPN Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its Supernus Pharmaceuticals (SUPN) stake by 18% in Q2 2026, selling an estimated $1.25M and leaving 116,160 shares worth $5.4M. The position accounts for 0.09% of the portfolio, ranked #266.

Susquehanna Portfolio Strategies first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.43M in Q3 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Susquehanna Portfolio Strategies held 116,160 shares of Supernus Pharmaceuticals worth $5.4M as of Q2 2026.
  • Susquehanna Portfolio Strategies sold 26,022 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
  • Supernus Pharmaceuticals made up 0.09% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #266 holding.
  • Susquehanna Portfolio Strategies first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Susquehanna Portfolio Strategies's Supernus Pharmaceuticals position peaked at $7.43M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.